Global Alzheimer’s Disease Phase 3 Clinical Trial Completes Enrollment

Global Alzheimer’s Disease Phase 3 Clinical Trial Completes Enrollment
Takeda Pharmaceutical Company and partner Zinfandel Pharmaceuticals announced the completion of patient enrollment in the TOMMORROW Phase 3 Clinical Trial, one of the largest studies ever to be executed in mild cognitive impairment and Alzheimer's disease (AD). Previous research has shown that individuals who develop mild cognitive impairment (MCI) are at an increased risk of developing Alzheimer's disease or another form of dementia, with yearly conversion rates of approximately 15 percent. So far, no medication studied has been shown to reliably delay the onset of Alzh
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *